Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases

Launched by UNIVERSITY OF ABERDEEN · Aug 11, 2017

Keywords

ClinConnect Summary

Eligible participants will be identified from patients with inflammatory rheumatic diseases attending major secondary care rheumatology services in the United Kingdom. Potential participants will be identified using local databases/clinic lists and will then be mailed a pre-study invite, which will include questions about fatigue. Potentially eligible participants will be invited to attend a baseline assessment.

Once it has been confirmed at the baseline assessement that they are eligible to take part in the study, the consented participant will be allocated to one of three treatment group...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • be ≥ 18 years at the time of consent
• • have been diagnosed with rheumatoid arthritis (RA), systemic lupus erythematous (SLE), axial spondyloarthritis (AxSpA) or psoriatic arthritis (PSA) by a rheumatologist
• • report fatigue to be a persistent problem
• • have access to a telephone landline or mobile telephone and/or internet based audio/video calls
• • give permission for researchers to access their hospital medical notes
• • currently be under the care of a secondary care physician
• • have stable disease as evidenced by no change in immunomodulatory therapy within the last three months based on the hospital medical record
• Exclusion Criteria:
• • there are significant abnormalities of thyroid function (TSH levels) on the most recent blood test done within the last three months
• • there is evidence of severe anaemia (haemoglobin levels) on the most recent blood test done within the last three months
• • there is evidence of severe renal dysfunction (eGFR) on the most recent blood test done within the last three months
• • they have a medical condition which would make the proposed interventions unsuitable, e.g. significant heart disease
• • they are pregnant
• • they are unable to understand English sufficiently to take part in the intervention
• • they are unable to provide written informed consent
• • they are not willing to be randomised
• • they are currently participating in an interventional clinical trial